Brief: Sino Biopharmaceutical Says LM-350 CDH17 Antibody-Drug Conjugate Receives Clinical Trial Approval From China's NMPA
18/11/2025 10:19
Nov 18 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK: LM-350 CDH17 ANTIBODY-DRUG CONJUGATE RECEIVES CLINICAL TRIAL APPROVAL FROM CHINA'S NMPA Further company coverage: 1177.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsBrief: Sino Biopharmaceutical Announces Share Purchase Plan For HK$2 Billion
Brief: Sino Biopharmaceutical Says Marketing Application For M701 Accepted By China In May 2026
Brief: Sino Biopharmaceutical Says Zongertinib Approved By NMPA China
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment (updated)
HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up